Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2006

01-06-2006 | Commentary

Bone versus breast density

Author: Jack Cuzick

Published in: Breast Cancer Research | Issue 3/2006

Login to get access

Abstract

The common link with oestrogen levels suggests that bone mineral density and mammographic density might also be linked. One study found weak support for this, but another study failed to provide confirmation. Overall, the relationship is very weak, if it exists at all. Other factors such as weight-bearing exercise, which have opposing impacts on these variables, may have a more dominant effect.
Appendix
Available only for authorised users
Literature
1.
Dite GS, Wark JD, Giles GG, English DR, McCredie MRE, Hopper JL: Is there a positive association between mammographic density and bone mineral density?. Breast Cancer Res. 2006, 8: 401-10.1186/bcr1383.CrossRefPubMedPubMedCentral
2.
Crandall C, Palla S, Reboussin BA, Ursin G, Greendale GA: Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study. Breast Cancer Res. 2005, 7: R922-R928. 10.1186/bcr1327.CrossRefPubMedPubMedCentral
3.
Boyd NF, Byng R, Jong E: Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian national breast screening study. J Natl Cancer Inst. 1995, 87: 670-675.CrossRefPubMed
4.
Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, et al: Post-menopausal serum androgens, oestrogens, and breast cancer risk. Endocr Relat Cancer. 2002, 12: 1071-1082. 10.1677/erc.1.01038.CrossRef
5.
Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002, 94: 606-616.CrossRefPubMed
6.
Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G: Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst. 2003, 95: 30-37.CrossRefPubMed
7.
Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR: Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 1996, 276: 1404-1408. 10.1001/jama.276.17.1404.CrossRefPubMed
8.
Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW: Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004, 96: 621-628.CrossRefPubMed
Metadata
Title
Bone versus breast density
Author
Jack Cuzick
Publication date
01-06-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1407

Other articles of this Issue 3/2006

Breast Cancer Research 3/2006 Go to the issue

Review

Array-CGH and breast cancer

Research article

Keratin 6 is not essential for mammary gland development

Review

High-throughput genomic technology in research and clinical management of breast cancer. Evolving landscape of genetic epidemiological studies

Research article

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

Research article

The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

Research article

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits